Metabolomic and proteomic profiling of exosome from 9 healthy subjects and 9 patients diagnosed with amyotrophic lateral sclerosis are shared (ALS). Serum EVs were obtained from subjects included in the protocol METABOMU (NCT02670226). Proteomics and metabolipidomics analyses were performed following EVs purification through Size Exclusion Chromatography and characterization by Nanoparticle Tracking Analysis (NTA). Proteomics (LC-MS/MS followed by TimsTOF Pro Mass Spectrometer), metabobolipidomics (Q-Exactive mass spectrometer).